U.S. Pharmaceutical

Our Engagement

women
United States of America

Supporting Communities and Collaborating for Care

America’s health challenges are always evolving — and no one can address them alone. That’s why we collaborate with the best and brightest minds who share our passion for advancing standards of care that address these challenges.

At Bayer, we’re making investments and building partnerships to reveal new paths that address individuals’ unmet health needs, so they can receive care at the right place and the right time.
 

in the lab
The New Bayer Research and Innovation Center

Also known as BRIC, this center aims to strengthen collaboration between Bayer’s research and development teams, its wholly-owned subsidiaries and its many external partners — including some of the Cambridge, MA area’s brightest scientific minds.
 

Read More

Our Collaborations and Partnerships

Supporting Access to Health Across the U.S.

>$562M pharma products

provided to almost 15,500 un/under-insured​ in the U.S. in 2022.​

More than $75M

over the past five years donated as part of Bayer Fund.​

Provided >23,000

women access to family planning services in 2021.​
 

Discover More
A woman and an older woman are walking in the park.
Proactive Ways to Get Healthier as You Get Older
How we age is a collection of a number of factors. And a lot of them are in your control. Be proactive in creating the future you.
Read More
2 min read
A woman is working in a laboratory with yellow flasks.
Balancing act between innovative cancer medicines and generics
The Chinese government has eliminated tariffs and is reducing VAT on cancer drugs, putting more pressure on reimbursement negotiations and procurement processes to urge pharma companies to transfer this economic benefit to patients. This will put price pressure on cancer drugs, ideally without compromising on quality.
Read More
5 min read
A blurry image of people crossing a street at night.
Japan: protect innovation to protect patients
The Japanese government will soon announce their final decision on the drug pricing system reform. If proposed cuts to the price maintenance premium are implemented, security for high-risk research and development of pharmaceutical companies, who spend billions on developing new drugs, could be lost.
Read More
3 min read
Two women in lab coats looking at a piece of paper.
Investing in Wellness Strategies for an Actively Aging Society
Policy changes must make way for market innovation to enhance functional ability as we age, says Michael Hodin, CEO of the Global Coalition on Aging. 30 years from now, the new metric for success in healthcare will be wellness prevention and the preservation of functional ability.
Read More
4 min read
A woman is looking at a tablet while a doctor is talking to her.
Improving cancer care for ASEAN patients | Pharmaceuticals
In the countries that form the Association of South East Asian Nations (ASEAN), cancer is a disease that is sometimes overlooked.
Read More
10 min read
An older man and a young boy on a surfboard.
Healthy heart for healthy aging
For the first time in human history, we approach a future with more people over 60 than under 15. Organizations must proactively address the rising prevalence and economic impact of cardiovascular diseases to ensure a sustainable and healthy society tomorrow, namely by supporting scientific progress and innovation.
Read More
4 min read
An aerial view of a city at dusk.
Valuing innovative cancer medicines in China’s legal framework
The Chinese government has announced several new systems and measures in the last year that enforce the protection of Intellectual Property (IP). The new implementations accelerate the review and approval of innovative drugs and broaden financial coverage for cancer care.
Read More
5 min read
two physicians talk about the findings of the pages
Spotlight on China’s strategy to tackle cancer
The aging society and growing prevalence of cancer in China is placing a burden on health systems. Yet, from 2001 to 2016 only 30% of innovative medicines were available to Chinese patients. Recent healthcare reforms under Healthy China 2030 promote early diagnosis but still need to support innovative medicines.
Read More
4 min read
An aerial view of a busy highway in shanghai.
Healthy China 2030: Pressure on Prices Under Pooled Procurement | Pharmaceuticals
As part of Healthy China 2030, the Chinese government has opted to ramp up pressure on reimbursement negotiations and procurement processes.
Read More
4 min read
An image of a woman looking at a dna.
Gene Therapy May Defeat Previously Incurable Diseases | Pharmaceuticals
Gene therapy is considered the key to combating previously incurable diseases. In contrast to the traditional administration of drugs, a functional gene enables the body to produce the required proteins itself. Researchers are currently pursuing a promising approach for the treatment of hemophilia A, among other diseases.
Read More
4 min read
A group of people riding scooters on a city street.
Restructure improves quality and cost of healthcare in China
The Chinese Government has experienced a major personnel change and departmental shake-up to improve the overall health conditions of the Chinese people, enhancing prevention of diseases and improving health literacy. One of the three newly created health bodies will focus on tackling the rising prevalence of cancer.
Read More
5 min read
A girl running on the beach with a colorful kite.
Healthy China 2030: China's healthcare journey
The Chinese government has introduced major structural reforms to counter rising healthcare costs. Healthy China 2030 sets out China's long term approach to healthcare and shows their commitment to participating in global health governance and to achieve health equity and better access for all.
Read More
7 min read
2 min read